{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:28:08Z","timestamp":1791865688064,"version":"4.3.4"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG048218"],"award-info":[{"award-number":["R01AG048218"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG052404"],"award-info":[{"award-number":["R21AG052404"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS11978"],"award-info":[{"award-number":["R01NS11978"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS075233"],"award-info":[{"award-number":["R01NS075233"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006221","name":"United States - Israel Binational Science Foundation","doi-asserted-by":"publisher","award":["2019248"],"award-info":[{"award-number":["2019248"]}],"id":[{"id":"10.13039\/100006221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Neurosci"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41593-020-00778-1","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T17:39:51Z","timestamp":1612201191000},"page":"297-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":184,"title":["Gene-based therapies for neurodegenerative diseases"],"prefix":"10.1038","volume":"24","author":[{"given":"Jichao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-2735","authenticated-orcid":false,"given":"Subhojit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","volume":"28","author":"S Somanathan","year":"2020","unstructured":"Somanathan, S., Calcedo, R. & Wilson, J. M. Adenovirus\u2013antibody complexes contributed to lethal systemic inflammation in a gene therapy trial. Mol. Ther. 28, 784\u2013793 (2020).","journal-title":"Mol. Ther."},{"key":"778_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"778_CR3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/oxfordjournals.jhered.a105747","volume":"38","author":"CE Keeler","year":"1947","unstructured":"Keeler, C. E. Gene therapy. J. Hered. 38, 294\u2013298 (1947).","journal-title":"J. Hered."},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky, V. et al. Safety and tolerability of BAN2401\u2014a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody. Alzheimers Res. Ther. 8, 14 (2016).","journal-title":"Alzheimers Res. Ther."},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"102","author":"E Hudry","year":"2019","unstructured":"Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 102, 839\u2013862 (2019).","journal-title":"Neuron"},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"LK Huang","year":"2020","unstructured":"Huang, L. K., Chao, S. P. & Hu, C. J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 18 (2020).","journal-title":"J. Biomed. Sci."},{"key":"778_CR8","doi-asserted-by":"publisher","unstructured":"Bedbrook, C. N., Deverman, B. E. & Gradinaru, V. Viral strategies for targeting the central and peripheral nervous systems. Annu. Rev. Neurosci. https:\/\/doi.org\/10.1146\/annurev-neuro-080317-062048 (2018).","DOI":"10.1146\/annurev-neuro-080317-062048"},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","volume":"4","author":"P Leone","year":"2012","unstructured":"Leone, P. et al. Long-term follow-up after gene therapy for canavan disease. Sci. Transl Med. 4, 165ra163 (2012).","journal-title":"Sci. Transl Med."},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1002\/jgm.3015","volume":"20","author":"SL Ginn","year":"2018","unstructured":"Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2017: an update. J. Gene Med. 20, e3015 (2018).","journal-title":"J. Gene Med."},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381\u2013390 (2009).","journal-title":"J. Infect. Dis."},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi, F. et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419\u2013422 (2007).","journal-title":"Nat. Med."},{"key":"778_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.gt.3303037","volume":"15","author":"H Petry","year":"2008","unstructured":"Petry, H. et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther. 15, 54\u201360 (2008).","journal-title":"Gene Ther."},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"17158","DOI":"10.1073\/pnas.0909520106","volume":"106","author":"Y Lu","year":"2009","unstructured":"Lu, Y. & Song, S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc. Natl Acad. Sci. USA 106, 17158\u201317162 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR15","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.cellimm.2019.103997","volume":"346","author":"SN Ashley","year":"2019","unstructured":"Ashley, S. N., Somanathan, S., Giles, A. R. & Wilson, J. M. TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy. Cell Immunol. 346, 103997 (2019).","journal-title":"Cell Immunol."},{"key":"778_CR16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/hum.2020.182","volume":"31","author":"JM Wilson","year":"2020","unstructured":"Wilson, J. M. & Flotte, T. R. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum. Gene Ther. 31, 695\u2013696 (2020).","journal-title":"Hum. Gene Ther."},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"107453","DOI":"10.1016\/j.pharmthera.2019.107453","volume":"207","author":"NF Nidetz","year":"2020","unstructured":"Nidetz, N. F. et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol. Ther. 207, 107453 (2020).","journal-title":"Pharmacol. Ther."},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR\u2013Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490\u2013507 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/d41573-019-00139-z","volume":"18","author":"A Mullard","year":"2019","unstructured":"Mullard, A. First in vivo CRISPR candidate enters the clinic. Nat. Rev. Drug Discov. 18, 656 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","volume":"11","author":"FD Urnov","year":"2010","unstructured":"Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636\u2013646 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","volume":"14","author":"JK Joung","year":"2013","unstructured":"Joung, J. K. & Sander, J. D. TALENs: a widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14, 49\u201355 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"778_CR24","doi-asserted-by":"publisher","first-page":"e3000665","DOI":"10.1371\/journal.pbio.3000665","volume":"18","author":"J Willems","year":"2020","unstructured":"Willems, J. et al. ORANGE: a CRISPR\/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons. PLoS Biol. 18, e3000665 (2020).","journal-title":"PLoS Biol."},{"key":"778_CR25","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.1093\/nar\/gkz475","volume":"47","author":"SH Park","year":"2019","unstructured":"Park, S. H. et al. Highly efficient editing of the \u03b2-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res. 47, 7955\u20137972 (2019).","journal-title":"Nucleic Acids Res."},{"key":"778_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-319-74470-4_5","volume":"1056","author":"K Sugaya","year":"2018","unstructured":"Sugaya, K. & Vaidya, M. Stem cell therapies for neurodegenerative diseases. Adv. Exp. Med. Biol. 1056, 61\u201384 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"778_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229\u2013233 (2019).","journal-title":"Nat. Med."},{"key":"778_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07971-8","volume":"10","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage. Nat. Commun. 10, 53 (2019).","journal-title":"Nat. Commun."},{"key":"778_CR29","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","volume":"165","author":"MW Popp","year":"2016","unstructured":"Popp, M. W. & Maquat, L. E. Leveraging rules of nonsense-mediated mRNA decay for genome engineering and personalized medicine. Cell 165, 1319\u20131322 (2016).","journal-title":"Cell"},{"key":"778_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.omtn.2019.04.015","volume":"16","author":"CH Lau","year":"2019","unstructured":"Lau, C. H., Ho, J. W., Lo, P. K. & Tin, C. Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637\u2013649 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"778_CR31","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980\u2013D985 (2014).","journal-title":"Nucleic Acids Res."},{"key":"778_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"778_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"778_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","volume":"35","author":"YB Kim","year":"2017","unstructured":"Kim, Y. B. et al. Increasing the genome-targeting scope and precision of base editing with engineered Cas9\u2013cytidine deaminase fusions. Nat. Biotechnol. 35, 371\u2013376 (2017).","journal-title":"Nat. Biotechnol."},{"key":"778_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"778_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","volume":"569","author":"J Grunewald","year":"2019","unstructured":"Grunewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433\u2013437 (2019).","journal-title":"Nature"},{"key":"778_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41592-020-0832-x","volume":"17","author":"E Zuo","year":"2020","unstructured":"Zuo, E. et al. A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects. Nat. Methods 17, 600\u2013604 (2020).","journal-title":"Nat. Methods"},{"key":"778_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"778_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9\u201321 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"778_CR40","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aba4624","volume":"367","author":"BR Leavitt","year":"2020","unstructured":"Leavitt, B. R. & Tabrizi, S. J. Antisense oligonucleotides for neurodegeneration. Science 367, 1428\u20131429 (2020).","journal-title":"Science"},{"key":"778_CR41","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/acs.biochem.9b00046","volume":"58","author":"G Chen","year":"2019","unstructured":"Chen, G., Katrekar, D. & Mali, P. RNA-guided adenosine deaminases: advances and challenges for therapeutic RNA editing. Biochemistry 58, 1947\u20131957 (2019).","journal-title":"Biochemistry"},{"key":"778_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh, O. O. et al. RNA targeting with CRISPR\u2013Cas13. Nature 550, 280\u2013284 (2017).","journal-title":"Nature"},{"key":"778_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","volume":"173","author":"S Konermann","year":"2018","unstructured":"Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665\u2013676.e14 (2018).","journal-title":"Cell"},{"key":"778_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1126\/science.aax7063","volume":"365","author":"OO Abudayyeh","year":"2019","unstructured":"Abudayyeh, O. O. et al. A cytosine deaminase for programmable single-base RNA editing. Science 365, 382\u2013386 (2019).","journal-title":"Science"},{"key":"778_CR45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"778_CR46","doi-asserted-by":"publisher","first-page":"43741","DOI":"10.1074\/jbc.M112.372318","volume":"287","author":"KJ Han","year":"2012","unstructured":"Han, K. J. et al. Ubiquitin-specific protease 9\u00d7 deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron. J. Biol. Chem. 287, 43741\u201343752 (2012).","journal-title":"J. Biol. Chem."},{"key":"778_CR47","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl Med. 3, 72ra18 (2011).","journal-title":"Sci. Transl Med."},{"key":"778_CR48","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 92, e2492\u2013e2506 (2019).","journal-title":"Neurology"},{"key":"778_CR49","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"778_CR50","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"778_CR51","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin, N. A. et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688\u2013693 (2014).","journal-title":"Science"},{"key":"778_CR52","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1089\/hum.2017.255","volume":"29","author":"M Zhou","year":"2018","unstructured":"Zhou, M. et al. Seamless genetic conversion of SMN2 to SMN1 via CRISPR\/Cpf1 and single-stranded oligodeoxynucleotides in spinal muscular atrophy patient-specific induced pluripotent stem cells. Hum. Gene Ther. 29, 1252\u20131263 (2018).","journal-title":"Hum. Gene Ther."},{"key":"778_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy, S. et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr. Pulmonol. 54, 179\u2013185 (2019).","journal-title":"Pediatr. Pulmonol."},{"key":"778_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/dneu.22556","volume":"78","author":"J Sun","year":"2018","unstructured":"Sun, J. & Roy, S. The physical approximation of APP and BACE-1: a key event in Alzheimer\u2019s disease pathogenesis. Dev. Neurobiol. 78, 340\u2013347 (2018).","journal-title":"Dev. Neurobiol."},{"key":"778_CR55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nn.4188","volume":"19","author":"U Das","year":"2016","unstructured":"Das, U. et al. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat. Neurosci. 19, 55\u201364 (2016).","journal-title":"Nat. Neurosci."},{"key":"778_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","volume":"168","author":"YA Huang","year":"2017","unstructured":"Huang, Y. A., Zhou, B., Wernig, M. & Sudhof, T. C. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion. Cell 168, 427\u2013441.e21 (2017).","journal-title":"Cell"},{"key":"778_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-160836","volume":"56","author":"E Doran","year":"2017","unstructured":"Doran, E. et al. Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP. J. Alzheimers Dis. 56, 459\u2013470 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"778_CR58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nrd.2017.155","volume":"16","author":"C Li","year":"2017","unstructured":"Li, C. & Gotz, J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat. Rev. Drug Discov. 16, 863\u2013883 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"778_CR59","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"MH Tuszynski","year":"2005","unstructured":"Tuszynski, M. H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551\u2013555 (2005).","journal-title":"Nat. Med."},{"key":"778_CR60","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2008.10.004","volume":"215","author":"AH Nagahara","year":"2009","unstructured":"Nagahara, A. H. et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp. Neurol. 215, 153\u2013159 (2009).","journal-title":"Exp. Neurol."},{"key":"778_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"MS Rafii","year":"2018","unstructured":"Rafii, M. S. et al. Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol. 75, 834\u2013841 (2018).","journal-title":"JAMA Neurol."},{"key":"778_CR62","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/hum.2019.367","volume":"31","author":"MJ Castle","year":"2020","unstructured":"Castle, M. J. et al. Postmortem analysis in a clinical trial of AAV2\u2013NGF gene therapy for Alzheimer\u2019s disease identifies a need for improved vector delivery. Hum. Gene Ther. 31, 415\u2013422 (2020).","journal-title":"Hum. Gene Ther."},{"key":"778_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41434-018-0010-2","volume":"25","author":"AH Nagahara","year":"2018","unstructured":"Nagahara, A. H. et al. MR-guided delivery of AAV2\u2013BDNF into the entorhinal cortex of non-human primates. Gene Ther. 25, 104\u2013114 (2018).","journal-title":"Gene Ther."},{"key":"778_CR64","doi-asserted-by":"publisher","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481 (2017).","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"778_CR65","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/mtna.2014.30","volume":"3","author":"R Sud","year":"2014","unstructured":"Sud, R., Geller, E. T. & Schellenberg, G. D. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids 3, e180 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"778_CR66","doi-asserted-by":"publisher","unstructured":"Velazquez, R. et al. Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. Aging Cell https:\/\/doi.org\/10.1111\/acel.12775 (2018).","DOI":"10.1111\/acel.12775"},{"key":"778_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou, L. et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 8, 15295 (2017).","journal-title":"Nat. Commun."},{"key":"778_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","volume":"37","author":"JT Yu","year":"2014","unstructured":"Yu, J. T., Tan, L. & Hardy, J. Apolipoprotein E in Alzheimer\u2019s disease: an update. Annu. Rev. Neurosci. 37, 79\u2013100 (2014).","journal-title":"Annu. Rev. Neurosci."},{"key":"778_CR69","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501\u2013518 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"778_CR70","doi-asserted-by":"publisher","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry, E. et al. Gene transfer of human APOE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl Med. 5, 212ra161 (2013).","journal-title":"Sci. Transl Med."},{"key":"778_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"JB Rosenberg","year":"2018","unstructured":"Rosenberg, J. B. et al. AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum. Gene Ther. Clin. Dev. 29, 24\u201347 (2018).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"778_CR72","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"Y-T Lin","year":"2018","unstructured":"Lin, Y.-T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141\u20131154.e7 (2018).","journal-title":"Neuron"},{"key":"778_CR73","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","volume":"11","author":"B Gyorgy","year":"2018","unstructured":"Gyorgy, B. et al. CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer\u2019s disease. Mol. Ther. Nucleic Acids 11, 429\u2013440 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"778_CR74","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","volume":"26","author":"JL Chang","year":"2018","unstructured":"Chang, J. L. et al. Targeting amyloid-\u03b2 precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production. Mol. Ther. 26, 1539\u20131551 (2018).","journal-title":"Mol. Ther."},{"key":"778_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrn.2017.29","volume":"18","author":"UC Muller","year":"2017","unstructured":"Muller, U. C., Deller, T. & Korte, M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci. 18, 281\u2013298 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"778_CR76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1076-8","volume":"568","author":"S Iyer","year":"2019","unstructured":"Iyer, S. et al. Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. Nature 568, 561\u2013565 (2019).","journal-title":"Nature"},{"key":"778_CR77","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00401-015-1498-9","volume":"131","author":"R Fol","year":"2016","unstructured":"Fol, R. et al. Viral gene transfer of APPs\u03b1 rescues synaptic failure in an Alzheimer\u2019s disease mouse model. Acta Neuropathol. 131, 247\u2013266 (2016).","journal-title":"Acta Neuropathol."},{"key":"778_CR78","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1002\/mds.22062","volume":"23","author":"JA Obeso","year":"2008","unstructured":"Obeso, J. A. et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson\u2019s disease. Mov. Disord. 23, S548\u2013S559 (2008).","journal-title":"Mov. Disord."},{"key":"778_CR79","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662\u20131669 (2009).","journal-title":"Neurology"},{"key":"778_CR80","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"G Mittermeyer","year":"2012","unstructured":"Mittermeyer, G. et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum. Gene Ther. 23, 377\u2013381 (2012).","journal-title":"Hum. Gene Ther."},{"key":"778_CR81","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/hum.2011.162","volume":"23","author":"W San Sebastian","year":"2012","unstructured":"San Sebastian, W. et al. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2\u2013hAADC with a novel delivery platform in nonhuman primate striatum. Hum. Gene Ther. 23, 210\u2013217 (2012).","journal-title":"Hum. Gene Ther."},{"key":"778_CR82","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"S Palfi","year":"2014","unstructured":"Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 383, 1138\u20131146 (2014).","journal-title":"Lancet"},{"key":"778_CR83","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1523\/JNEUROSCI.22-02-00592.2002","volume":"22","author":"MS Baron","year":"2002","unstructured":"Baron, M. S., Wichmann, T., Ma, D. & DeLong, M. R. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J. Neurosci. 22, 592\u2013599 (2002).","journal-title":"J. Neurosci."},{"key":"778_CR84","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.jcbfm.9600364","volume":"27","author":"ME Emborg","year":"2007","unstructured":"Emborg, M. E. et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow. Metab. 27, 501\u2013509 (2007).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"778_CR85","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1074549","volume":"298","author":"J Luo","year":"2002","unstructured":"Luo, J. et al. Subthalamic GAD gene therapy in a Parkinson\u2019s disease rat model. Science 298, 425\u2013429 (2002).","journal-title":"Science"},{"key":"778_CR86","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369, 2097\u20132105 (2007).","journal-title":"Lancet"},{"key":"778_CR87","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt, P. A. et al. AAV2\u2013GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309\u2013319 (2011).","journal-title":"Lancet Neurol."},{"key":"778_CR88","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","volume":"2","author":"M Niethammer","year":"2017","unstructured":"Niethammer, M. et al. Long-term follow-up of a randomized AAV2\u2013GAD gene therapy trial for Parkinson\u2019s disease. JCI Insight 2, e90133 (2017).","journal-title":"JCI Insight"},{"key":"778_CR89","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00002512-199914040-00003","volume":"14","author":"TJ Collier","year":"1999","unstructured":"Collier, T. J. & Sortwell, C. E. Therapeutic potential of nerve growth factors in Parkinson\u2019s disease. Drugs Aging 14, 261\u2013287 (1999).","journal-title":"Drugs Aging"},{"key":"778_CR90","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1096\/fj.07-8797com","volume":"22","author":"YH Chen","year":"2008","unstructured":"Chen, Y. H. et al. MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J. 22, 261\u2013275 (2008).","journal-title":"FASEB J."},{"key":"778_CR91","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1089\/hum.2009.103","volume":"20","author":"X Su","year":"2009","unstructured":"Su, X. et al. Safety evaluation of AAV2\u2013GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum. Gene Ther. 20, 1627\u20131640 (2009).","journal-title":"Hum. Gene Ther."},{"key":"778_CR92","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","volume":"7","author":"WJ Marks Jr.","year":"2008","unstructured":"Marks, W. J. Jr. et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial. Lancet Neurol. 7, 400\u2013408 (2008).","journal-title":"Lancet Neurol."},{"key":"778_CR93","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks, W. J. Jr et al. Gene delivery of AAV2\u2013neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164\u20131172 (2010).","journal-title":"Lancet Neurol."},{"key":"778_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"RT Bartus","year":"2011","unstructured":"Bartus, R. T. et al. Bioactivity of AAV2\u2013neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains. Mov. Disord. 26, 27\u201336 (2011).","journal-title":"Mov. Disord."},{"key":"778_CR95","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","volume":"80","author":"RT Bartus","year":"2013","unstructured":"Bartus, R. T. et al. Safety\/feasibility of targeting the substantia nigra with AAV2\u2013neurturin in Parkinson patients. Neurology 80, 1698\u20131701 (2013).","journal-title":"Neurology"},{"key":"778_CR96","doi-asserted-by":"publisher","first-page":"163ra156","DOI":"10.1126\/scitranslmed.3004676","volume":"4","author":"M Decressac","year":"2012","unstructured":"Decressac, M. et al. \u03b1-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl Med. 4, 163ra156 (2012).","journal-title":"Sci. Transl Med."},{"key":"778_CR97","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41586-020-2388-4","volume":"582","author":"H Qian","year":"2020","unstructured":"Qian, H. et al. Reversing a model of Parkinson\u2019s disease with in situ converted nigral neurons. Nature 582, 550\u2013556 (2020).","journal-title":"Nature"},{"key":"778_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"778_CR99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","volume":"533","author":"F Soldner","year":"2016","unstructured":"Soldner, F. et al. Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression. Nature 533, 95\u201399 (2016).","journal-title":"Nature"},{"key":"778_CR100","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1096\/fj.07-9348com","volume":"22","author":"J Fuchs","year":"2008","unstructured":"Fuchs, J. et al. Genetic variability in the SNCA gene influences \u03b1-synuclein levels in the blood and brain. FASEB J. 22, 1327\u20131334 (2008).","journal-title":"FASEB J."},{"key":"778_CR101","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1172\/JCI64502","volume":"125","author":"AD Zharikov","year":"2015","unstructured":"Zharikov, A. D. et al. shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model. J. Clin. Invest. 125, 2721\u20132735 (2015).","journal-title":"J. Clin. Invest."},{"key":"778_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43772-9","volume":"9","author":"T Uehara","year":"2019","unstructured":"Uehara, T. et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting \u03b1-synuclein as a novel therapy for Parkinson\u2019s disease. Sci. Rep. 9, 7567 (2019).","journal-title":"Sci. Rep."},{"key":"778_CR103","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor, B. et al. Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol. Ther. 26, 2638\u20132649 (2018).","journal-title":"Mol. Ther."},{"key":"778_CR104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","volume":"11","author":"MJ Benskey","year":"2018","unstructured":"Benskey, M. J. et al. Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity. Front. Mol. Neurosci. 11, 36 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"778_CR105","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2010.115","volume":"18","author":"OS Gorbatyuk","year":"2010","unstructured":"Gorbatyuk, O. S. et al. In vivo RNAi-mediated \u03b1-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 18, 1450\u20131457 (2010).","journal-title":"Mol. Ther."},{"key":"778_CR106","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"778_CR107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do, J., McKinney, C., Sharma, P. & Sidransky, E. Glucocerebrosidase and its relevance to Parkinson disease. Mol. Neurodegener. 14, 36 (2019).","journal-title":"Mol. Neurodegener."},{"key":"778_CR108","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537\u20133542 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR109","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito, G. et al. AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol. Ther. 25, 2727\u20132742 (2017).","journal-title":"Mol. Ther."},{"key":"778_CR110","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jnr.21949","volume":"87","author":"PN Gandhi","year":"2009","unstructured":"Gandhi, P. N., Chen, S. G. & Wilson-Delfosse, A. L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson\u2019s disease. J. Neurosci. Res. 87, 1283\u20131295 (2009).","journal-title":"J. Neurosci. Res."},{"key":"778_CR111","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-319-49969-7_13","volume":"14","author":"JM Hatcher","year":"2017","unstructured":"Hatcher, J. M., Choi, H. G., Alessi, D. R. & Gray, N. S. Small-molecule inhibitors of LRRK2. Adv. Neurobiol. 14, 241\u2013264 (2017).","journal-title":"Adv. Neurobiol."},{"key":"778_CR112","doi-asserted-by":"publisher","first-page":"e66164","DOI":"10.1371\/journal.pone.0066164","volume":"8","author":"D Ness","year":"2013","unstructured":"Ness, D. et al. Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLoS ONE 8, e66164 (2013).","journal-title":"PLoS ONE"},{"key":"778_CR113","doi-asserted-by":"publisher","first-page":"273ra215","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji, R. N. et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl Med. 7, 273ra215 (2015).","journal-title":"Sci. Transl Med."},{"key":"778_CR114","doi-asserted-by":"publisher","first-page":"e80705","DOI":"10.1371\/journal.pone.0080705","volume":"8","author":"MA Baptista","year":"2013","unstructured":"Baptista, M. A. et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS ONE 8, e80705 (2013).","journal-title":"PLoS ONE"},{"key":"778_CR115","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao, H. T. et al. LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol. Ther. Nucleic Acids 8, 508\u2013519 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"778_CR116","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross, C. A. & Tabrizi, S. J. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83\u201398 (2011).","journal-title":"Lancet Neurol."},{"key":"778_CR117","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"778_CR118","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"778_CR119","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JHD-199003","volume":"8","author":"FB Rodrigues","year":"2019","unstructured":"Rodrigues, F. B., Ferreira, J. J. & Wild, E. J. Huntington\u2019s disease clinical trials corner: June 2019. J. Huntingtons Dis. 8, 363\u2013371 (2019).","journal-title":"J. Huntingtons Dis."},{"key":"778_CR120","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers, M. M. et al. AAV5\u2013miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model. Mol. Ther. 26, 2163\u20132177 (2018).","journal-title":"Mol. Ther."},{"key":"778_CR121","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau, R. L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol. Ther. 17, 1053\u20131063 (2009).","journal-title":"Mol. Ther."},{"key":"778_CR122","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek, L. M. et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum. Gene Ther. 25, 461\u2013474 (2014).","journal-title":"Hum. Gene Ther."},{"key":"778_CR123","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol. Ther. 19, 2152\u20132162 (2011).","journal-title":"Mol. Ther."},{"key":"778_CR124","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin, R. et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197\u20131209 (2012).","journal-title":"Brain"},{"key":"778_CR125","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359\u20133364 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR126","doi-asserted-by":"publisher","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","volume":"13","author":"P Dietrich","year":"2017","unstructured":"Dietrich, P., Johnson, I. M., Alli, S. & Dragatsis, I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 13, e1006846 (2017).","journal-title":"PLoS Genet."},{"key":"778_CR127","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin, J. W. et al. Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum. Mol. Genet. 25, 4566\u20134576 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"778_CR128","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1089\/hum.2007.116","volume":"19","author":"PH van Bilsen","year":"2008","unstructured":"van Bilsen, P. H. et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts. Hum. Gene Ther. 19, 710\u2013719 (2008).","journal-title":"Hum. Gene Ther."},{"key":"778_CR129","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/mt.2014.153","volume":"22","author":"AL Southwell","year":"2014","unstructured":"Southwell, A. L. et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther. 22, 2093\u20132106 (2014).","journal-title":"Mol. Ther."},{"key":"778_CR130","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister, E. L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr. Biol. 19, 774\u2013778 (2009).","journal-title":"Curr. Biol."},{"key":"778_CR131","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-189001","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues, F. B. & Wild, E. J. Huntington\u2019s disease clinical trials corner: February 2018. J. Huntingtons Dis. 7, 89\u201398 (2018).","journal-title":"J. Huntingtons Dis."},{"key":"778_CR132","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"B Zeitler","year":"2019","unstructured":"Zeitler, B. et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat. Med. 25, 1131\u20131142 (2019).","journal-title":"Nat. Med."},{"key":"778_CR133","doi-asserted-by":"publisher","unstructured":"Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R. & Gitler, A. D. ALS genetics: gains, losses, and implications for future therapies. Neuron https:\/\/doi.org\/10.1016\/j.neuron.2020.08.022 (2020).","DOI":"10.1016\/j.neuron.2020.08.022"},{"key":"778_CR134","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1126\/science.281.5384.1851","volume":"281","author":"LI Bruijn","year":"1998","unstructured":"Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851\u20131854 (1998).","journal-title":"Science"},{"key":"778_CR135","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290\u20132296 (2006).","journal-title":"J. Clin. Invest."},{"key":"778_CR136","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435\u2013442 (2013).","journal-title":"Lancet Neurol."},{"key":"778_CR137","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller, T. et al. Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109\u2013119 (2020).","journal-title":"N. Engl. J. Med."},{"key":"778_CR138","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","volume":"21","author":"KD Foust","year":"2013","unstructured":"Foust, K. D. et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 21, 2148\u20132159 (2013).","journal-title":"Mol. Ther."},{"key":"778_CR139","doi-asserted-by":"publisher","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","volume":"3","author":"T Gaj","year":"2017","unstructured":"Gaj, T. et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 3, eaar3952 (2017).","journal-title":"Sci. Adv."},{"key":"778_CR140","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","volume":"383","author":"C Mueller","year":"2020","unstructured":"Mueller, C. et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 383, 151\u2013158 (2020).","journal-title":"N. Engl. J. Med."},{"key":"778_CR141","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"778_CR142","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn.2016.38","volume":"17","author":"AR Haeusler","year":"2016","unstructured":"Haeusler, A. R., Donnelly, C. J. & Rothstein, J. D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 17, 383\u2013395 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"778_CR143","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535\u2013550 (2016).","journal-title":"Neuron"},{"key":"778_CR144","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"MH Tuszynski","year":"2015","unstructured":"Tuszynski, M. H. et al. Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol. 72, 1139\u20131147 (2015).","journal-title":"JAMA Neurol."},{"key":"778_CR145","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","volume":"85","author":"CW Christine","year":"2019","unstructured":"Christine, C. W. et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease. Ann. Neurol. 85, 704\u2013714 (2019).","journal-title":"Ann. Neurol."},{"key":"778_CR146","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3233\/JPD-199001","volume":"9","author":"K McFarthing","year":"2019","unstructured":"McFarthing, K., Prakash, N. & Simuni, T. Clinical trial highlights: 1. Gene therapy for Parkinson\u2019s, 2. Phase 3 study in focus\u2014INTEC Pharma\u2019s accordion pill, 3. Clinical trials resources. J. Parkinsons Dis. 9, 251\u2013264 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"778_CR147","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","volume":"33","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs 33, 919\u2013932 (2019).","journal-title":"CNS Drugs"},{"key":"778_CR148","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635 (2018).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41593-020-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-020-00778-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-020-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T15:07:33Z","timestamp":1674918453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41593-020-00778-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1038\/s41593-020-00778-1","relation":{},"ISSN":["1097-6256","1546-1726"],"issn-type":[{"value":"1097-6256","type":"print"},{"value":"1546-1726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. and S.R. have applied for patents related to gene editing in AD (US patent application number 16251970). S.R. is also the scientific founder of, advisor to, and owns equity in CRISPRAlz.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}